This study reappraised the comparative outcomes of a surgery-first approach versus neoadjuvant chemotherapy (NACT) in patients with stage I (cT1c) triple-negative breast cancer (TNBC), evaluating oncologic trade-offs in this early-stage subgroup.
The paper's full text was not available for detailed extraction; specific outcome data, sample sizes, and statistical results could not be verified from the provided metadata alone.
Clinicians managing cT1c TNBC should carefully weigh the benefits of NACT (pathologic complete response rate, potential de-escalation) against surgery-first strategies, particularly for this early-stage group where the evidence base is still evolving.
Explore related topics
